Published by Iain Gilbert on 7th September 2022
(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.
URL: http://www.digitallook.com/dl/news/story/32943298/...